One study reported that among breast cancer patients with diabetes, no differences in the incidence of weekly paclitaxel-related peripheral neuropathy were found for the type of treatment (insulin vs. oral agents vs. diet) [36]. This evidence concerns the gene INS and breast carcinoma.